31
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Heart-type fatty-acid-binding protein (FABP3) is a lysophosphatidic acid-binding protein in human coronary artery endothelial cells

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          • We have identified FABP3 as an LPA carrier protein in human coronary artery endothelial cells (HCAECs).

          • Administration of LPA to HCAECs resulted in a dose-dependent increase in PPARγ activation.

          • LPA-induced PPARγ activation was abolished when the FABP3 expression was reduced using small interfering RNA (siRNA).

          • FABP3 governs the transcriptional activities of LPA by targeting them to cognate PPARγ in the nucleus.

          Abstract

          Fatty-acid-binding protein 3, muscle and heart (FABP3), also known as heart-type FABP, is a member of the family of intracellular lipid-binding proteins. It is a small cytoplasmic protein with a molecular mass of about 15 kDa. FABPs are known to be carrier proteins for transporting fatty acids and other lipophilic substances from the cytoplasm to the nucleus, where these lipids are released to a group of nuclear receptors such as peroxisome proliferator-activated receptors (PPARs). In this study, using lysophosphatidic acid (LPA)-coated agarose beads, we have identified FABP3 as an LPA carrier protein in human coronary artery endothelial cells (HCAECs). Administration of LPA to HCAECs resulted in a dose-dependent increase in PPARγ activation. Furthermore, the LPA-induced PPARγ activation was abolished when the FABP3 expression was reduced using small interfering RNA (siRNA). We further show that the nuclear fraction of control HCAECs contained a significant amount of exogenously added LPA, whereas FABP3 siRNA-transfected HCAECs had a decreased level of LPA in the nucleus. Taken together, these results suggest that FABP3 governs the transcriptional activities of LPA by targeting them to cognate PPARγ in the nucleus.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

          The past several years have seen an explosive increase in our understanding of the transcriptional basis of adipose cell differentiation. In particular, a key role has been illustrated for PPAR-gamma, a member of the nuclear hormone receptor superfamily. PPAR-gamma has also been recently identified as the major functional receptor for the thiazolidinedione class of insulin-sensitizing drugs. This review examines the evidence that has implicated this transcription factor in the processes of adipogenesis and systemic insulin action. In addition, several models are discussed that may explain how a single protein can be involved in these related but distinct physiological actions. I also point out several important areas where our knowledge is incomplete and more research is needed. Finally, I discuss how advances in our understanding of nuclear receptor function, particularly the docking of cofactors in a ligand-dependent fashion, should lead to improved drugs that utilize the PPAR-gamma system for the treatment of insulin resistance.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology.

            Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors that belong to the steroid/thyroid/retinoic acid receptor superfamily. All their characterized target genes encode proteins that participate in lipid homeostasis. The recent finding that antidiabetic thiazolidinediones and adipogenic prostanoids are ligands of one of the PPARs reveals a novel signaling pathway that directly links these compounds to processes involved in glucose homeostasis and lipid metabolism including adipocyte differentiation. A detailed understanding of this pathway could designate PPARs as targets for the development of novel efficient treatments for several metabolic disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Activators of the nuclear receptor PPARgamma enhance colon polyp formation.

              A high-fat diet increases the risk of colon, breast and prostate cancer. The molecular mechanism by which dietary lipids promote tumorigenesis is unknown. Their effects may be mediated at least in part by the peroxisome proliferator-activated receptors (PPARs). These ligand-activated nuclear receptors modulate gene expression in response to fatty acids, lipid-derived metabolites and antidiabetic drugs. To explore the role of the PPARs in diet-induced carcinogenesis, we treated mice predisposed to intestinal neoplasia with a synthetic PPARgamma ligand. Reflecting the pattern of expression of PPARgamma in the gastrointestinal tract, treated mice developed a considerably greater number of polyps in the colon but not in the small intestine, indicating that PPARgamma activation may provide a molecular link between a high-fat diet and increased risk of colorectal cancer.
                Bookmark

                Author and article information

                Contributors
                Journal
                FEBS Open Bio
                FEBS Open Bio
                FEBS Open Bio
                Elsevier
                2211-5463
                31 October 2014
                31 October 2014
                2014
                : 4
                : 947-951
                Affiliations
                [a ]Department of Hematology and Immunology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
                [b ]Endowed Research Division of Human Welfare Sciences, Ochanomizu University, 2-1-1 Ohtsuka, Bunkyo-ku, Tokyo 112-8610, Japan
                [c ]Science and Education Center, Ochanomizu University, 2-1-1 Ohtsuka, Bunkyo-ku, Tokyo 112-861, Japan
                [d ]Institute for Biomedical Sciences, Shinshu University Interdisciplinary Cluster for Cutting Edge Research, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
                [e ]Clinical Pharmacology Educational Center, Nihon Pharmaceutical University, Ina-machi, Saitama 362-0806, Japan
                Author notes
                [* ]Corresponding author. ttamotsu@ 123456kanazawa-med.ac.jp
                Article
                S2211-5463(14)00103-X
                10.1016/j.fob.2014.10.014
                4239478
                25426414
                17cfa366-9ea9-49ce-a1fa-d2579031e136
                © 2014 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).

                History
                : 19 September 2014
                : 26 October 2014
                : 28 October 2014
                Categories
                Article

                fabp3, fatty-acid-binding protein 3, muscle and heart,hcaecs, human coronary artery endothelial cells,lpa, lysophosphatidic acid,lpc, lysophosphatidylcholine,pparγ, peroxisome proliferator-activated receptor gamma,sirna, small interfering rna,fabp3,lysophosphatidic acid,hcaec,peroxisome proliferator-activated receptor gamma

                Comments

                Comment on this article